Follow
Jonathan Hollick
Jonathan Hollick
Unknown affiliation
Verified email at breakpointtx.com
Title
Cited by
Cited by
Year
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
S Lain, JJ Hollick, J Campbell, OD Staples, M Higgins, M Aoubala, ...
Cancer cell 13 (5), 454-463, 2008
5942008
2, 6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)
JJ Hollick, BT Golding, IR Hardcastle, N Martin, C Richardson, ...
Bioorganic & medicinal chemistry letters 13 (18), 3083-3086, 2003
1502003
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition …
JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ...
Journal of medicinal chemistry 50 (8), 1958-1972, 2007
1002007
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins
AR McCarthy, L Pirrie, JJ Hollick, S Ronseaux, J Campbell, M Higgins, ...
Bioorganic & medicinal chemistry 20 (5), 1779-1793, 2012
662012
Pilot screening programme for small molecule activators of p53
RG Berkson, JJ Hollick, NJ Westwood, JA Woods, DP Lane, S Lain
International journal of cancer 115 (5), 701-710, 2005
652005
P53 activating compounds
S Lain, DP Lane, MJR Stark, AR McCarthy, JJ Hollick, NJ Westwood
US Patent 8,501,991, 2013
212013
Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen
OD Staples, JJ Hollick, J Campbell, M Higgins, AR McCarthy, V Appleyard, ...
Cell Cycle 7 (21), 3417-3427, 2008
162008
The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen
AR McCarthy, JJ Hollick, NJ Westwood
Seminars in cancer biology 20 (1), 40-45, 2010
132010
Synthesis and biological evaluation of functionalised tetrahydro-β-carboline analogues as inhibitors of Toxoplasma gondii invasion
JGA Walton, S Patterson, G Liu, JD Haraldsen, JJ Hollick, AMZ Slawin, ...
Organic & Biomolecular Chemistry 7 (15), 3049-3060, 2009
132009
Pyrimidine derivatives as protein kinase inhibitors
JJ Hollick, SD Jones, CJ Flynn, MG Thomas
US Patent 8,563,542, 2013
92013
Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia
S Moureau, E Pohler, K Kroboth, C Saladino, C MacKay, J Hollick, ...
European Journal of Cancer 1 (69), S117, 2016
52016
Discovery
S Lain, JJ Hollick, J Campbell, OD Staples, M Higgins, M Aoubala, ...
vivo, 0
5
Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization
S Frame, C Aspinall, R O'Neil, J Hollick, S Taylor, T Hupp, D Blake, ...
Experimental and Molecular Therapeutics, 2012
32012
Application of combinatorial chemistry for the identification of pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase
JJ Hollick, BT Golding, RJ Griffin, IR Hardcastle, JJJ Leahy, N Martin, ...
14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, 2002
12002
The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations
S Moureau, C MacKay, C Saladino, E Pohler, K Kroboth, J Hollick, ...
Cancer Research 77 (13_Supplement), 4178-4178, 2017
2017
(") TargetDBR"-A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair …
JJ Hollick, L Abriola, F Bono, D Hegan, P Klingbeil, Y Liu, R Sundaram, ...
MOLECULAR CANCER RESEARCH 15, 2017
2017
Abstract B25:“TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate …
JJ Hollick, L Abriola, F Bono, D Hegan, P Klingbeil, Y Liu, R Sundaram, ...
Molecular Cancer Research 15 (4_Supplement), B25-B25, 2017
2017
Pochodne pirymidyny jako inhibitory kinaz białkowych
JJ Hollick, SD Jones, CJ Flynn, MG Thomas
2016
Pyrimidine derivatives as protein kinase inhibitors
JJ Hollick, SD Jones, CJ Flynn, MG Thomas
US Patent 9,493,471, 2016
2016
Derivados de pirimidina como inhibidores de proteína cinasa
JJ Hollick, SD Jones, CJ Flynn, MG Thomas
2016
The system can't perform the operation now. Try again later.
Articles 1–20